Central Laboratories Applications & Studies

  1. A Successful Full-Service, Randomized Pancreatic Cancer Phase II Trial 5/18/2023

    Learn how a clinical-stage biopharmaceutical company was able to reach a unanimous decision after a safety review committee data review meeting to close Phase II and advance to Phase III.

  2. Enhancing Clinical Trials By Linking Them To RWD 5/16/2023

    Learn how integrating participant trial data and real-world data into a standard EDC system can promote success in obtaining IRB approval.

  3. Emerging Biotech Saves Over $300K On Phase I Oncology Trial 4/24/2023

    Discover how one platform was able to provide operational efficiencies, data integrity, and savings, enabling the advancement of a clinical program during economic uncertainty.

  4. Using IRT Data To Automate And Optimize Clinical Supply 4/17/2023

    Learn how clinical teams can save between $150,000 and $1 million in annual drug and shipping costs through automated supply optimization.

  5. How To Double High-Performing Site Count In A Priority Indication 3/13/2023

    A top 10 biopharmaceutical company wanted to expand its site list in a priority indication and better understand how existing sites in their database performed. Find out what happened next.

  6. BMS Adopts A New Clinical Data Architecture 2/6/2023

    Learn how Bristol Myers Squibb was able to optimize data review processes to streamline and improve access to clinical trial records.

  7. Optimizing Data Services For Digital Trials With A Clinical Data Cloud 2/6/2023

    Learn how internal processes and comprehensive clinical data services for digital trials can be improved through the utilization of data clouds.

  8. Digital/Hybrid Trials Deliver Greater ROI Than Traditional Trials 2/2/2023

    In this paper, Tufts CSDD outlines why and how modernized clinical trials can drive greater savings (up to $40,000,000 per study) than traditional trials.

  9. Trial Rescue: Site Selection And Prioritization 12/16/2022

    A large pharmaceutical company was looking to validate its list of 100+ US sites for a chronic auto-immune disease study. Leveraging medical claims data, a site-level analysis was conducted to identify relevant patients meeting the trial’s I/E criteria.

  10. Medicenna Gains Precedent-Setting FDA Approval 12/8/2022

    Learn how Medicenna was able to leverage Synthetic Control Arm (SCA) to bolster Phase 2 findings and gain FDA approval to design a hybrid external control arm for their Phase 3 registrational trial.